SCHEMBL6325956

SCHEMBL6325956

O=C(Nc1ccc(O)cc1)Nc1nnc(-c2cc(Cl)cc(Cl)c2O)s1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BLM P54132 9/20 0.53
▸ RAB9A P51151 6/20 0.53
▸ SMN1; SMN2 Q16637 4/20 0.53
▸ HTT P42858 4/20 0.53
▸ KDM4E B2RXH2 4/20 0.53
▸ MCL1 Q07820 4/20 0.53
▸ POLB P06746 4/20 0.51
▸ LMNA P02545 2/20 0.50
▸ GAA P10253 2/20 0.50
▸ WRN Q14191 2/20 0.50
▸ MEN1 O00255 1/20 0.50
▸ ALDH1A1 P00352 1/20 0.50
▸ DNMT1 P26358 1/20 0.50
▸ DUSP3 P51452 1/20 0.50
▸ CACNA1B Q00975 1/20 0.50
▸ APBA1 Q02410 1/20 0.50
▸ KMT2A Q03164 1/20 0.50
▸ TDP1 Q9NUW8 1/20 0.50
▸ HPN P05981 1/20 0.49
▸ NPC1 O15118 4/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6445978 0.87 SNCA (0.47) RAB9ASMN1; SMN2HTTKDM4EPOLB
SCHEMBL6324529 0.87 MAPT (0.52) BLMRAB9ASMN1; SMN2HTTKDM4E
SCHEMBL6323345 0.87 RAB9A (0.50) BLMRAB9ASMN1; SMN2HTTKDM4E
SCHEMBL6329444 0.87 MEN1 (0.58) BLMRAB9ASMN1; SMN2HTTKDM4E
SCHEMBL6329453 0.86 BLM (0.52) BLMRAB9ASMN1; SMN2HTTKDM4E
SCHEMBL6323159 0.86 BLM (0.57) BLMRAB9ASMN1; SMN2HTTKDM4E
SCHEMBL6325012 0.86 RAB9A (0.55) BLMRAB9ASMN1; SMN2HTTKDM4E
SCHEMBL6325969 0.84 BLM (0.45) BLMRAB9ASMN1; SMN2HTTKDM4E
SCHEMBL6324404 0.83 CBS (0.54) BLMRAB9ASMN1; SMN2HTTKDM4E
SCHEMBL6329503 0.83 MAPT (0.58) RAB9ASMN1; SMN2HTTKDM4EPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050124664-A1 Urea thiadiazole inhibitors of plasminogen activator inhibior-1 BRISTOL-MYERS SQUIBB CO. 2005-06-09 — — US claimed
US-20050124664-A1 Urea thiadiazole inhibitors of plasminogen activator inhibior-1 BRISTOL-MYERS SQUIBB CO. 2005-06-09 — — US disclosed
US-20050113438-A1 Substituted indoles WYETH (US) 2005-05-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050124664-A1 Urea thiadiazole inhibitors of plasminogen activator inhibior-1 SERPINE1, SERPINC1, SERPINB1 BLM 2929/4885RAB9A 3129/4885SMN1; SMN2 3158/4885
US-20050113438-A1 Substituted indoles IDO2, IDO1, INMT BLM 3187/4885RAB9A 3184/4885SMN1; SMN2 3610/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback